Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagen®) in children

Eye

Volumn 18, Issue 1, 2004, Pages 24-26

  Bowman, R J C ^a,b   Cope, J ^a   Nischal, K K ^a,b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alphagen ; Brimonidine 0.2 ; Children; Side effects

Indexed keywords

ACETAZOLAMIDE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; DORZOLAMIDE; EYE DROPS; LATANOPROST; PILOCARPINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DROWSINESS; DRUG DOSAGE FORM; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EYE IRRITATION; EYE PAIN; FATIGUE; FEMALE; GLAUCOMA; HUMAN; HYPERTENSION; INFANT; MALE; SYNCOPE;

EID: 0842280808     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700520     Document Type: Article

References (12)

1. Korsch E, Grote A, Seybold M, Soditt V. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma. Eur J Pediatr 1999; 158(8): 685.
2. Carlsen JO, Zabriskie NA, Kwon YH, Barbe ME, Scott WE. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 1999; 128(2): 255-256.
3. Walters G, Taylor RH. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma. Eye 1999; 13 (Part 6): 797-798.
4. Berlin RJ, Lee UT, Samples JR et al. Ophthalmic drops causing coma in an infant. J Pediatr 2001; 138(3): 441-443.
5. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996; 41 (Suppl 1): S9-S18.
6. Robin AL, Bornstein Y. Selectivity of site of action and systemic effects of topical alpha agonists. Curr Opin Ophthalmol 1998; 9(2): 30-33.
7. Derick RJ, Robin AL, Walters TR et al. Brimonidine tartrate. A one month dose response study. Ophthalmol 1997; 104: 131-136.
8. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000; 84(7): 710-713.
9. Serle J and the brimonidine study group III. A comparison of the safety and efficacy of twice daily rimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol 1996; 41 (Suppl 1): S39-S47.
10. Detry-Morel M, Dutrieux C. Treatment of glaucoma with brimonidine (Alphagan 0.2%). J Fr Ophtalmol 2000; 23(8): 763-768 (French).
11. Kim DD. A case of suspected alphagan-induced psychosis. Arch Ophthalmol 2000; 118(8): 1132-1133.
12. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J Am Assoc Pediatr Ophthalmol Strab 2001; 5(5): 281-284.